Abstract
Objective: To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.
Methods: A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.
Results: Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.
Conclusion: The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.
Keywords: Cytokines, dengue, doxycycline, mortality.
Recent Patents on Anti-Infective Drug Discovery
Title:Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels
Volume: 10 Issue: 1
Author(s): Terry M. Fredeking, Jorge E. Zavala-Castro, Pedro Gonzalez-Martinez, William Moguel-Rodríguez, Ernesto C. Sanchez, Michael J. Foster and Fredi A. Diaz-Quijano
Affiliation:
Keywords: Cytokines, dengue, doxycycline, mortality.
Abstract: Objective: To determine the effect of doxycycline treatment on cytokine levels, including tumor necrosis factor (TNF) and interleukin 6 (IL-6), and mortality in dengue patients at high risk of complication.
Methods: A group of dengue hemorrhagic fever patients (n=231) were randomized to receive either standard supportive care or supportive care in addition to oral doxycycline twice daily for 7 days. Dengue virus infection was confirmed by PCR using multiple primers. Serum samples were obtained at days 0, 3, 5 and 7 and tested for levels of TNF and IL-6.
Results: Doxycycline-treated group presented a 46% lower mortality than that observed in the untreated group (11.2% [13/116] vs 20.9% [24/115], respectively, p=0.05). Moreover, administration of doxycycline resulted in a significant (p<0.01) decrease in levels of TNF and IL-6 versus controls in the tests performed during follow-up (day 3, 5 and 7). Patients who died in both groups possessed significantly (p<0.01) higher levels of TNF and IL-6 compared to those who survived at all-time points.
Conclusion: The above findings suggest that doxycycline can provide a clinical benefit to dengue patients at high risk of complications. This effect could be mediated by decreasing pro-inflammatory cytokine levels.
Export Options
About this article
Cite this article as:
Fredeking M. Terry, Zavala-Castro E. Jorge, Gonzalez-Martinez Pedro, Moguel-Rodríguez William, Sanchez C. Ernesto, Foster J. Michael and Diaz-Quijano A. Fredi, Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels, Recent Patents on Anti-Infective Drug Discovery 2015; 10 (1) . https://dx.doi.org/10.2174/1574891X10666150410153839
DOI https://dx.doi.org/10.2174/1574891X10666150410153839 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Microbial Sensors Based on Nanostructures
Recent Patents on Nanomedicine Animal Models for Obsessive-Compulsive Disorder
Current Neuropharmacology Self-Organizing Maps for the Classification of Gallic Acylate Polyphenols as HSV-1 Inhibitors
Medicinal Chemistry Thiosemicarbazides: Updates on Antivirals Strategy
Mini-Reviews in Medicinal Chemistry Synopsis on Managment Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development
Current Topics in Medicinal Chemistry Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Current Drug Metabolism Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Cytokine Network in HIV Infection
Current Molecular Medicine Sudden Infant Death Following Hexavalent Vaccination: A Neuropathologic Study
Current Medicinal Chemistry The Application of Micro-Analytical Techniques to Biomedical Analysis
Current Pharmaceutical Analysis mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Coumarins as Inhibitors of HIV Reverse Transcriptase
Current HIV Research Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety